Granules India gets USFDA nod for generic Glycopyrrolate oral solution
Granules India gains ANDA approval for Trazodone tablets
Granules Quarterly Results- FY25-Q1
Granules India`s Q1 profit nearly triples on strong demand
Annual Financial Results – FY24
Granules India Announced ANDA Approval for Colchicine Capsules
Granules India Annual Financial Results – FY24
Granules India’s Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India has successfully completed the US Food and Drug Administration (FDA) inspection between April 8-12 2024, resulting in zero 483 observations.
Pharmaceutical major Granules India announced on Friday, April 12, that its Unit V facility located at Anakapally, Visakhapatnam in Andhra…
Granules, NIPER-Mohali ink pact to establish centre of excellence